KHKatriona Harrison

Katriona Harrison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katriona Harrison has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring Structure−Activity Relationships by Engineering Modified Thrombin Inhibitors from the Flea Xenopsylla cheopis

    by Angus S. Mackay, Joshua W. C. Maxwell, Katriona Harrison, Harry P. Aitken, José A. Manso, Pedro M. Martins, Pedro José Barbosa Pereira, Daniel J. Ford, Jorge Ripoll-Rozada, Richard J. Payne

    Engineering of post-translationally sulfated polypeptides from hematophagous organisms has shown promise for the development of novel anticoagulants with improved therapeutic potential. Here, we describe the development of a high-throughput peptide engineering workflow to facilitate rapid assembly of libraries of modified peptide analogues. Library members were designed from the privileged chimeric anticoagulant sulfo-XC43-Hiru, comprised of a peptide fragment of XC43 (from the rat flea Xenopsylla cheopis) and a sulfopeptide fragment of hirudin (from the medicinal leech, Hirudo medicinalis). Focus was placed on exploring the influence of non-native structural motifs through the incorporation of non-canonical amino acids at a number of strategic sites. The thrombin inhibitory activity and cleavage resistance of each analogue is profiled and provides valuable insight into the relationship between the sequence and biological activity of these molecules.

  • Open Access

    De novo cyclic peptides allow visualisation of the monomeric and functional amyloid conformations of the kinase RIPK3

    by Jessica A. Buchanan, Olivia Lavidis, Nicholas Shields, Katriona Harrison, Huy T. Nguyen, Richard J. Payne, Toby Passioura, Megan Steain, Margaret Sunde

    Receptor interacting protein kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signalling. Its function is orchestrated through RIP homotypic interaction motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualising full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed random non-standard peptide integrated discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualising RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.


  • Open Access

    De novo Cyclic Peptides Allow Visualisation of the Monomeric and Functional Amyloid Conformations of the Kinase RIPK3

    by Jessica A. Buchanan, Olivia Lavidis, Nicholas Shields, Katriona Harrison, Huy T. Nguyen, Richard J. Payne, Toby Passioura, Megan Steain, Margaret Sunde

    Receptor Interacting Protein Kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signaling. Its function is orchestrated through RIP Homotypic Interaction Motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualizing full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed Random Non-standard Peptide Integrated Discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualizing RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.

  • Discovery of Selective Cyclic d-Sulfopeptide Ligands of the Chemokine CCL22 via Mirror-Image mRNA Display with Genetic Reprogramming

    by Belinda B. Zhang, Katriona Harrison, Yichen Zhong, Joshua W. C. Maxwell, Daniel J. Ford, Liam P. Calvey, Sean S. So, Francis C. Peterson, Brian F. Volkman, Martin J. Stone, et al.

    Chemokines are small proteins involved in recruiting leukocytes to sites of inflammation via interactions with specific cell surface receptors. CCL22 is a chemokine known to play a critical role in inflammatory diseases such as atopic dermatitis and asthma; inhibition of this chemokine therefore represents an attractive therapeutic strategy. Herein, we describe the discovery of cyclic d-sulfopeptide inhibitors of CCL22 identified through mirror-image mRNA display with genetic reprogramming. Chemical synthesis of mirror-image d-CCL22 enabled screening of a cyclic peptide library comprised of all l-amino acids, with reprogramming of l-sulfotyrosine to mimic the presence of this post-translational modification on native chemokine receptors. Enriched macrocyclic peptides were prepared in their mirror-image d-form and assessed for binding against native l-CCL22. The most potent ligand, a plasma-stable d-cyclic peptide bearing four d-sulfotyrosine residues, exhibited nanomolar affinity for CCL22, high selectivity over other chemokines, and nanomolar inhibition of CCL22 signaling through CCR4. This work highlights the vast potential of mirror-image mRNA display technology for discovering proteolytically stable d-peptide inhibitors of protein-protein interactions relevant across a range of therapeutic indications.


  • Synthesis and applications of mirror-image proteins

    by Katriona Harrison, Angus S. Mackay, Lucas Kambanis, Joshua W. C. Maxwell, Richard J. Payne

    The homochirality of biomolecules in nature, such as DNA, RNA, peptides and proteins, has played a critical role in establishing and sustaining life on Earth. This chiral bias has also given synthetic chemists the opportunity to generate molecules with inverted chirality, unlocking valuable new properties and applications. Advances in the field of chemical protein synthesis have underpinned the generation of numerous ‘mirror-image’ proteins (those comprised entirely of d-amino acids instead of canonical l-amino acids), which cannot be accessed using recombinant expression technologies. This Review seeks to highlight recent work on synthetic mirror-image proteins, with a focus on modern synthetic strategies that have been leveraged to access these complex biomolecules as well as their applications in protein crystallography, drug discovery and the creation of mirror-image life.